These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37309470)

  • 21. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
    Black CJ; Burr NE; Quigley EMM; Moayyedi P; Houghton LA; Ford AC
    Gastroenterology; 2018 Dec; 155(6):1753-1763. PubMed ID: 30144426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New pharmacological treatment options for irritable bowel syndrome with constipation.
    Nusrat S; Miner PB
    Expert Opin Emerg Drugs; 2015; 20(4):625-36. PubMed ID: 26548544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in pharmacological treatment of irritable bowel syndrome.
    Lazaraki G; Chatzimavroudis G; Katsinelos P
    World J Gastroenterol; 2014 Jul; 20(27):8867-85. PubMed ID: 25083060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
    King AJ; Siegel M; He Y; Nie B; Wang J; Koo-McCoy S; Minassian NA; Jafri Q; Pan D; Kohler J; Kumaraswamy P; Kozuka K; Lewis JG; Dragoli D; Rosenbaum DP; O'Neill D; Plain A; Greasley PJ; Jönsson-Rylander AC; Karlsson D; Behrendt M; Strömstedt M; Ryden-Bergsten T; Knöpfel T; Pastor Arroyo EM; Hernando N; Marks J; Donowitz M; Wagner CA; Alexander RT; Caldwell JS
    Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
    Layer P; Stanghellini V
    Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lubiprostone: RU 0211, SPI 0211.
    Drugs R D; 2005; 6(4):245-8. PubMed ID: 15991886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome.
    Mousavi T; Nikfar S; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):583-604. PubMed ID: 32380874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Irritable bowel syndrome - less irritable, or better treatments?
    Travers P; Lacy BE; Cangemi DJ
    Curr Opin Gastroenterol; 2024 Jan; 40(1):27-33. PubMed ID: 38078610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.
    Halmos EP; Power VA; Shepherd SJ; Gibson PR; Muir JG
    Gastroenterology; 2014 Jan; 146(1):67-75.e5. PubMed ID: 24076059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Treatments from Inhibition of the Intestinal Sodium-Hydrogen Exchanger 3.
    Kovesdy CP; Adebiyi A; Rosenbaum D; Jacobs JW; Quarles LD
    Int J Nephrol Renovasc Dis; 2021; 14():411-420. PubMed ID: 34880650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current gut-directed therapies for irritable bowel syndrome.
    Chang HY; Kelly EC; Lembo AJ
    Curr Treat Options Gastroenterol; 2006 Jul; 9(4):314-23. PubMed ID: 16836950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin.
    Shekhar C; Monaghan PJ; Morris J; Issa B; Whorwell PJ; Keevil B; Houghton LA
    Gastroenterology; 2013 Oct; 145(4):749-57; quiz e13-4. PubMed ID: 23872499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging therapies in the management of Irritable Bowel Syndrome (IBS).
    Elwing JE; Atassi H; Rogers BD; Sayuk GS
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):55-73. PubMed ID: 35266839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis.
    Barberio B; Savarino EV; Black CJ; Ford AC
    Clin Gastroenterol Hepatol; 2022 May; 20(5):e923-e944. PubMed ID: 34425274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of Kolofort for the treatment of patients with irritable bowel syndrome].
    Tsukanov VV; Rzhavicheva OS; Vasjutin AV; Dunaevskaja OV; Tonkih JL; Bronnikova EP
    Ter Arkh; 2016; 88(8):40-45. PubMed ID: 27636926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research.
    Fehnel SE; Ervin CM; Carson RT; Rigoni G; Lackner JM; Coons SJ;
    Value Health; 2017 Apr; 20(4):618-626. PubMed ID: 28408004
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.